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The aim of this thesis was to develop drug encapsulation in chitosan nanoparticles for der-
mal patch formulations. The thesis project included the optimization of preparation protocols 
of drug capsulated nanoparticles by using a model drug and a variety of synthetic routes. 
Subsequently, the model drug was replaced by the local anesthetic drug, lidocaine. In addi-
tion, one part of the project was to develop a thin polymer film which incorporates lidocaine-
encapsulated chitosan nanoparticles. Ph.D. Didem Sen Karaman from Åbo Akademi Uni-
versity acted as a supervisor and an expert during this thesis project. The thesis was com-
missioned by the Pharmaceutical Sciences Laboratory at Åbo Akademi University. 
Nanotechnology refers to technology that utilizes nanosized materials with a diameter of 1-
100 nanometers of materials. Nanoparticles have specific properties, based on their large 
surface area / mass ratio and specific physicochemical properties. When the material is 
processed to nanoscale, the chemical, physical and biological properties are either signifi-
cantly better or completely different as compared to conventional materials. 
Chitosan is a natural biopolymer which can be used in drug delivery due to its many good 
properties. For example, it is non-toxic, biodegradable and has bactericidal and growth-in-
hibiting effects. Lidocaine is a widely used drug for local anesthesia. Its effect is based on 
the fact that it is nonionic, which means it can easily pass through the cell membrane. Lido-
caine has the ability to close sodium channels of nerve cells and thus prevent the transmis-
sion of nerve impulses.  
Thin polymer films are being developed for use in drug delivery. They have a number of 
advantages, including the possibility of designing different drug dosing on the natural poly-
mer matrix. In addition, a thin polymer film which incorporates drug-encapsulated nanopar-
ticles modify the release rate of the drug, reduce toxicity and enhance the therapeutic effi-
ciency. 
The obtained results revealed that encapsulation of lidocaine into chitosan nanoparticles 
improves the release of drug compared to free lidocaine in the patch formulation.  In addition, 
the flux of drug from the film is higher when the formulation contains nanoparticles. However, 
the results showed that the nanoparticles’ incorporation route in the patches must be im-
proved. 
Keywords nanotechnology, nanoparticle, chitosan, dermal drug delivery, li-
docaine, local anesthetic, polymeric film, Franz cell diffusion 
 Tiivistelmä 
  
Tekijä 
Otsikko 
 
 
Sivumäärä 
Päivämäärä 
Aino Oisalo 
Lääkkeellä kapseloitujen kitosaaninanopartikkelien muotoilu 
paikallispuudutukseen käytettyyn iholaastariin 
 
33 sivua 
10.3.2017 
Tutkinto Insinööri (AMK) 
Koulutusohjelma Bio- ja elintarviketekniikka 
Suuntautumisvaihtoehto Biolääketeknologia 
Ohjaajat 
 
Professori Jessica Rosenholm 
Tohtori Didem Sen Karaman 
Lehtori Hannu Turunen 
Opinnäytetyön tavoitteena oli kehitellä paikallispuudutelaastari kitosaaninanopartikkeleja 
apuna käyttäen. Työhön kuului lääkeainetta sisältävien nanopartikkelien valmistamiseen liit-
tyvien olosuhteiden optimointi käyttäen erilaisia synteesireittejä, minkä jälkeen malliaine kor-
vattiin varsinaisella lääkeaineella. Lisäksi yksi osa tutkimusta oli kehitellä polymeerikalvo, 
johon lidokaiinilla kapseloitu kitosaaninanopartikkeli voidaan yhdistää. Opinnäytetyössä oh-
jaajana sekä asiantuntija-apuna toimi tohtori Didem Sen Karaman Åbo Akademista. Opin-
näytetyön toimeksiantajana toimi Åbo Akademi, farmasian tutkimuslaitos. 
 
Nanoteknologialla tarkoitetaan teknologiaa, jossa hyödynnetään nanokokoisia, halkaisijal-
taan 1 - 100 nanometriä olevia materiaaleja. Nanopartikkeleilla on erityisiä ominaisuuksia, 
jotka perustuvat niiden suureen pinta-alan ja massan suhteeseen ja erityisiin fysikaaliske-
miallisiin ominaisuuksiin. Kun materiaali pilkotaan nanomittakaavaan, sen kemialliset, fysi-
kaaliset ja biologiset ominaisuudet ovat joko huomattavasti parempia tai täysin erilaisia ver-
rattuna tavanomaisiin materiaaleihin. 
 
Kitosaani on luonnollinen biopolymeeri, jota voidaan käyttää apuna muun muassa lääkeai-
neiden annostelussa lukuisien hyvien ominaisuuksien ansiosta.  Se on muun muassa myr-
kytön, biohajoava ja sillä on bakteereja sekä tappava että kasvua estäviä vaikutuksia. Lido-
kaiini on laajalti käytetty lääkeaine paikallispuudutuksessa. Sen vaikutus perustuu siihen, 
että se on ionisoitumaton eli se läpäisee helposti solukalvon. Lidokaiini pystyy sulkemaan 
hermosolujen natriumkanavat ja näin ollen estää hermoimpulssien välittymisen. Ohuita po-
lymeerikalvoja kehitellään käytettäväksi lääkeannostelussa. Niillä on useita etuja, kuten 
mahdollisuus ohjelmoituun lääkeaineen annosteluun luonnollisesta polymeerimatriisista. Li-
säksi ohuet polymeerikalvot, joihin on yhdistetty lääkekapseloituja nanopartikkeleja, muok-
kaavat lääkkeiden vapautumisnopeutta, vähentävät myrkyllisyyttä sekä parantavat terapeut-
tista tehokkuutta. 
 
Saadut tulokset osoittivat, että laastarit, jotka sisälsivät kitosaaninanopartikkeleja vapautta-
vat kolme kertaa enemmän lääkeainetta verrattuna vain lidokaiinia sisältäviin laastareihin. 
Lisäksi lidokaiinin virtaus kalvosta on suurempi, kun formulaatio sisältää nanohiukkasia. Kui-
tenkin tulokset osoittivat, että polymeerikalvojen valmistusmenetelmää on kehitettävä. 
Avainsanat Nanoteknologia, nanopartikkeli, kitosaani, dermaallinen lää-
keannostelu, lidokaiini, paikallispuudutus, polymeerikalvo 
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1 Introduction 
Nanotechnology is a generic term for very small-scale technology (scale from 1 to 100 
nm). It offers possible keys to many current problems by means of smaller, lighter, faster 
and better-performing materials, components and systems. In drug delivery, nanotech-
nology is now an exponentially growing focus of research and development and it is 
being applied to improve drug delivery in several ways. 
Generally, drugs have problems such as poor stability, water insolubility, low selectivity, 
high toxicity, side effects, poor bioavailability and lack of selectivity. One of the biggest 
problems in therapeutic treatment is drug delivery. For example, in cancer treatments 
chemotherapy also kills normal, healthy cells along the way. The promise of nanotech-
nology in drug delivery is to deliver a drug selectively to the target site for enhanced 
efficacy with reduced side effects. 
Nanoparticles are widely used as drug carriers in pharmaceutical applications. There are 
different types of nanoparticles such as inorganic, polymeric, solid lipid, liposome, nano-
crystal, nanotube and dendrimer. Several materials as metal, carbon nanotubes, poly-
mers or other materials can be used for preparation of nanoparticles in a variety of med-
ical applications.  
Chitosan (CHT) is one of the most commonly used natural biomaterials, and it is made 
by treating the chitin shells of shrimp and other crustaceans. Chitosan nanoparticles as 
drug carriers have the advantage of providing controlled drug release, they can also aid 
to improve drug solubility and stability, enhance efficacy and reduce toxicity. In addition, 
chitosan is highly biocompatible. 
Lidocaine is one of the widely used drug for local anesthesia. Skin, the biggest organ in 
the body, has one of the functions to protect against toxic compounds as chemicals and 
new drug carrier techniques are needed. Nowadays, the markets have pharmaceutical 
applications (gels, patches, ointments) that include lidocaine hydrochloride (Xylocaine®) 
or a eutectic mixture of lidocaine hydrochloride and procaine hydrochloride (EMLA®). 
The development of local anesthetics applications for topical drug delivery using lipo-
somes and nanoparticles have been explored. One of the growing technique is incorpo-
ration of drugs into thin polymeric films by using, for example, nanoparticles. The thin 
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polymeric films have several benefits such as possibility of controlled delivery of drug by 
regulation of the nature of polymeric matrix. In addition, a thin polymer film which incor-
porates drug-encapsulated nanoparticles modifies the release rate of drugs, increasing 
bioadhesive properties and reducing toxicity as well as resulting in an improved thera-
peutic efficacy. 
The aim of this thesis project was to develop a thin polymeric film containing lidocaine-
encapsulated chitosan nanoparticles as a local anesthetic formulation. This thesis is part 
of the research run by Professor Jessica Rosenholm in the BioNanoMaterials group at 
the Pharmaceutical Sciences Laboratory, which is part of the Faculty of Science and 
Engineering at Åbo Akademi University. The BioNanoMaterials research group has three 
different main objectives. One of them is to develop functional nanoparticles for detec-
tion, tracking, diagnostic and therapeutic biomedical applications by smart design. They 
also synthesize composite nanostructures for improved bio-applicability and theranostic 
activity. In addition, they apply the developed nanomaterials for in vitro and in vivo drug 
targeting and biomedical imagining together with their collaborators.  
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2 Theoretical background 
2.1 Nanotechnology 
Nanotechnology takes part in several technology fields from electrics to cosmetics. Ac-
cording to the National Nanotechnology Initiative (NNI), nanoparticles have a diameter 
ranging from 1 to 100 nm. In this size range, it is possible to achieve control of matter at 
atomic and molecular scale. Nanotechnology offers possible solutions to many current 
problems by means of smaller, lighter, faster and better-performing materials, compo-
nents and systems compared to the bigger scale. (1) (2) 
However, nanotechnology refers to technologies in which the conscious use of na-
noscale structures to create new properties. Material properties change completely when 
the material consists of nanosized particles. Then the particle surface area relative to 
volume and mass is very large and causes physical, chemical and biological properties 
of a radical change in the substance. (2) 
2.2 Nanotechnology in drug delivery 
Nowadays nanotechnology has been applied to improve drug delivery in many ways, 
and the nanosystems provide several advantages. The reason is that nanostructured 
materials have shown promise as drug delivery systems because of their controlled- and 
sustained-release properties, subcellular size, and biocompatibility with tissue and cells. 
Especially, nanotechnology is adapted for non-soluble and hydrophobic drugs for im-
proving solubility. (3) (4) Various nanostructured materials were produced and applied 
to drug delivery such as nanoparticles, nanocapsules, nanotubes, micelles, nano- and 
micro emulsions and liposomes. (5) In this thesis, the focus was on nanoparticles. 
2.2.1 Nanoparticles 
Nanoparticles are one type of nanomaterials. Nanoparticles have been used as a phys-
ical approach to alter and improve the pharmacokinetic and pharmacodynamic proper-
ties of various types of drug molecules. Several materials such as metal (copper, zinc, 
gold, silver), carbon nanotubes, polymers (chitosan) or other materials can be used for 
preparation of nanoparticles in a variety of medical applications. Recent advancement in 
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nanotechnology has proven that nanoparticles can be used as drug carriers. Small size 
of particles (ranging from 10 nm to 100 nm) has several benefits. Various advantages of 
nanosizing are decreased fed/fasted variability and patient-to-patient variability, in-
creased oral bioavailability, rate of dissolution and surface area. In addition, nanosize 
applications offer less amount of dose required, enhanced solubility and more rapid on-
set of therapeutic action. (6) A variety of nanoparticles can be designed by considering 
the aim of the application.  Figure 1 shows different types of nanoparticles. 
 
Figure 1. Some types of nanoparticles: inorganic, polymeric, solid lipid, liposome, nanocrystal, 
nanotube and dendrimer. (7) 
In this thesis, polymeric nanoparticles (PNPs) is the type that was worked with. Most 
polymeric nanoparticles are biodegraded, biocompatible, non-toxic and degrade to pro-
duce readily cleared degradation by-products. They have been adopted as a preferred 
method for nanomaterial drug delivery. (7) PNPs have been extensively studied as par-
ticulate carriers in the pharmaceutical and medical fields. (8) Encapsulation strategies 
include polymers with absorbed drugs, dendritic molecules or coordination compounds 
with drugs bonded covalently or weakly attached, and artificial or natural micelles or lip-
osome vesicles containing nanodoses of insoluble or toxic drugs which can be selectively 
released on targets. (3) It is possible to prepare polymeric nanoparticles with different 
polymers, and in this thesis chitosan polymer was used for the preparation of nanoparti-
cles. 
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2.3 Chitosan 
Chitin is the second most important natural polymer after cellulose in the world, and chi-
tosan (CHT) is the most important derivative of chitin. When the degree of deacetylation 
of chitin reaches about 50%, it becomes soluble in aqueous acidic media and is called 
chitosan. (9) Figure 2 presents the structure of chitin and chitosan. Chitosan, N-acetyl-
d-glucosamine and β-(1,4)-linked d-glucosamine, is one of the most commonly used nat-
ural biomaterials. It is a hydrophilic polymer and a natural linear biopolyaminosaccharide. 
Chitosan is largely used in different applications as solutions, gels, or films and fibers, 
because it is being soluble in aqueous solutions. This polymer presents excellent bio-
compatibility, biodegradability and antimicrobial activity. (9) (10) (11) 
 
Figure 2. Structure of chitin and chitosan. Chitosan is delivered by deacetylation of chitin. (12)  
Generally, drugs have problems such as poor stability, water insolubility, low selectivity, 
high toxicity, unsensitiveness side effects, poor biodistribution and lack of selectivity. 
Drug carriers play a significant role in resolving these problems. In this thesis, chitosan 
nanoparticles were prepared and employed as drug carrier. Chitosan nanoparticles as 
drug carriers have the advantage of providing controlled drug release, they can also aid 
to improve drug solubility and stability, enhance efficacy and reduce toxicity. (13) 
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Properties of chitosan are shown in Figure 3. Chitosan nanoparticles are capable of 
passing through biological barriers in vivo because of their small size. In addition, chi-
tosan nanoparticles can deliver drugs to the lesion site to enhance efficacy, and modified 
nanoparticles also have other properties such as improved drug targeting. Being a nat-
ural product and having other good features such as low immunogenicity and low toxicity, 
chitosan is a renewable pharmaceutic adjuvant with good biocompatibility.  (13) (14) 
 
Figure 3. Properties of chitosan. 
The properties of chitosan allow it to be used in local anesthetic drug delivery in the skin, 
because chitosan is mucoadhesive in nature, reactive (it can be produced in many dif-
ferent forms), and most importantly, it has a positive charge under acidic conditions. 
Earlier studies show that chitosan hydrogels are non-cytotoxic and potential for extended 
drug release, making them promising local anesthetic delivery vehicles. (12) (15) 
2.4 Ionic gelation method 
Several methods for preparation of polymeric nanoparticles have been developed and 
one of them is ionic gelation method. It is also the one that is used in this work. The 
method is simple and mild, and involves the mixture of two aqueous phases at room 
temperature. 
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Figure 4. Schematic representation of the ionic gelation method. Tripolyphosphate is added to 
chitosan-drug solution dropwise with high speed mixing for making drug-loaded nano-
particles. TPP work as cross linker between chitosan and drug. (8) 
In ionic gelation method (Figure 4), based on the formation of complexation between the 
positively charged amine group of chitosan and negatively charged polyanion, such as 
tripolyphosphate (TPP) to form coacervates with a size in the range of nanometer.  TPP 
can be used for preparing chitosan nanoparticles because it is nontoxic, multivalent and 
able to form gels through ionic interactions. (8) (16) 
Nanoemulsions are nanosized emulsions, which are manufactured for improving the de-
livery of active pharmaceutical ingredients. A typical nanoemulsion contains oil, water 
and an emulsifier. Nanoemulsions have various advantages; for example, it can improve 
the bioavailability of the drug, it is non-toxic and non-irritant in nature as well has im-
proved physical stability. The most important benefit is that it helps to solubilize lipophilic 
drugs, and lidocaine (the drug that is used in this thesis) is a lipophilic molecule. (17) 
Due to unique properties of nanoemulsions, it is an attractive candidate for applications 
in the food, cosmetic, and pharmaceutical industries and in drug delivery applications. In 
this chapter, the focus will be on applications of nanoemulsions as building blocks for 
complex material synthesis to produce, for example, compartmentalized nanoparticles. 
One of the best-known application in polymer synthesis is emulsion polymerization. It 
means synthesis, where hydrophobic monomers contained in droplets are polymerized 
to create polymeric particles. Nanoemulsions have been utilized extensively in polymer 
synthesis. (17) (18) 
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Dichloromethane (DCM) is used for making nanoemulsions in nanotechnology. DCM is 
colorless, organic, water immiscible and highly polar oil compound that is usually used 
as a solvent. Chemical formula of DCM is CH2Cl2 and molar mass 84.93 g/mol. In this 
thesis project chitosan is dissolved in dichloromethane and the drug compound is dis-
solved in the polymer solution. It means that the mixture is emulsified in an aqueous 
solution containing surfactant and producing an oil-in-water emulsion. The advantages 
of this method are that it is simple, fast and economical. (19) (20) 
2.5 Local Anesthetic and Lidocaine Hydrochloride 
Local anesthesia includes numbing an area of the body using a type of medication called 
a local anesthetic. These medications can be used to treat painful conditions, prevent 
pain during a procedure or operation, or relieve pain after surgery. However, it is tempo-
rary pain killer without damaging nerves. (21) 
Skin is the biggest organ of the body. Skin performs functions such as protection against 
penetration of toxic exogenous compounds (e.g. chemicals, microbes), storage and syn-
thesis for water and lipids. In addition, skin acts as a water resistance barrier. Due to all 
properties of skin, skin has limited possibility of clinical applications. New drug carrier 
techniques are needed for dermal drug delivery. A number of carrier systems, for exam-
ple micro emulsions, liposomes, and nanoparticles have been investigated for dermal 
delivery of drugs. (15) (21) 
 
Figure 5. Structure of lidocaine hydrochloride monohydrate. 
Lidocaine is one of the oldest and widely used medicines that are used as local anes-
thetic agents after surgery, trauma, or medical procedures. It was discovered in the 
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1940s. Lidocaine reversibly closes the sodium channels of nerve cells and prevents the 
transmission of nerve impulses. It is a synthetic amide used chiefly in its hydrochloride 
salt form (C14H22N2O · HCl · H2O), in which from it was also used in this thesis project. 
The molecular weight of the hydrochloride from of lidocaine is 288.82 g/mol, and the 
structure of lidocaine hydrochloride is shown in Figure 5. 
The development of local anesthetics applications for dermal drug delivery using lipo-
somes and lipid nanoparticles have been explored. The idea for new nanosystems are 
modifying the release rate of drugs, increasing bioadhesive properties and reducing tox-
icity, resulting in an improved therapeutic efficacy. Nowadays, there are available com-
mercial formulations such as lidocaine and prilocaine cream (EMLA®, Astra Zeneca), 
lidocaine tape (Penles®, Wyeth) or lidocaine gel path (Lidoderm®, Endo Pharmaceuti-
cals). (15) (22) 
2.6 Thin polymeric film based patches for drug delivery 
Films that are made from natural, artificial, and synthetic polymers are called a polymeric 
film. The thickness of the film must be up to 0.2–0.3 mm so that it can be referred to as 
film; thicker polymeric materials are called sheets. Nowadays there is a growing interest 
in formulating drugs into thin polymeric films for various numbers of pharmaceutical ap-
plications such as oral strips, medical implants and for wound healing applications. (23) 
In many cases, the films can be of complex composition with different types of polymers 
with other components such as nanoparticles. The films are easy to handle, mechanically 
robust and should be non-toxic, biocompatible and biodegradable, so that it can be used 
as a platform for drug delivery. (24) 
The thin polymeric films have several benefits for being used efficiently as a drug release 
platform. The main advantage is possibility of programmed delivery of drug by regulation 
of the nature of polymeric matrix. Earlier studies have shown that thin films reduce the 
dose frequency and enhance the drug efficacy as well as the capabilities to improve the 
onset of drug action. For dermal drug delivery, complete skin contact is essential and 
flexible film applications can offer it. In addition, polymeric films are thin and flexible to 
be less obtrusive and more acceptable by the patient. (23) (24) 
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For local anesthesia, the drug should penetrate the stratum corneum and desensitize 
the underlying pain receptors within the skin. Since drug delivery to the skin presents 
both unique opportunities as well as problems owing to the skin structure, physiology, 
and barrier properties, thin polymeric film incorporated lidocaine-loaded nanoparticles 
could solve of the problems. Nanoparticles are used for targeting of topically applied 
drugs, increasing bioadhesive properties and reducing toxicity, resulting in an improved 
therapeutic efficacy. In addition, nanoparticles are smaller and lighter than original drug 
molecules, which make drug release from the film easier.  (15) 
 
Figure 6. Structure of bi-layered patch. 
There is exist various numbers of polymers that can be used to manufacture thin poly-
meric films. In this study, hydroxypropyl methyl cellulose (HPMC) and hydroxypropyl cel-
lulose (HPC) was used because earlier studies have shown desirable properties, such 
as thickness and elastics for the film. (25) Figure 6 presents the structure of the bi-lay-
ered patch that is used and produced in this thesis project. The backing membrane must 
be flexible and provide a good bond to the drug reservoir. In addition, it prevents drug 
from leaving the dosage from through the top. 
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3 Materials and Methods 
3.1 Materials 
Lidocaine (LID) hydrochloride monohydrate, chitosan (CHT) and tripolyphosphate (TPP) 
and dichloromethane (DCM) were purchased from Sigma Aldrich (St. Louis, MO). Hy-
droxypropyl methylcellulose polymer (HPMC), hydroxypropyl cellulose (HPC) and micro-
crystalline cellulose (MCC) were provided by Shin-Etsu Chemical (Chiyoda-ku, Tokyo, 
Japan). 
3.2 Dynamic Light Scattering and Zeta Potential 
Dynamic light scattering (DLS) is one of the most important tool in characterization of 
nanoparticles. The range of particle size that is allowed is 0.3nm – 10µm diameter. The 
basic principle of DLS is simple. It finds the particles and molecules that are in constant 
random thermal motion and diffuse at a speed related to their size. Generally, smaller 
particles diffuse faster than larger particles. 
Zeta potential (ZP) of particles is determined by measuring their velocity while they are 
moving due to electrophoresis. In addition, zeta potential depends of the speed that par-
ticles are moving. The speed is proportional to the field strength and their zeta potential. 
It is important to know the particles’ zeta potential because then it is possible to make 
reasonable choices about the chemistry of a formulation in order to select the most ap-
propriate materials to provide stability and to improve shelf life. 
3.3 Electron Microscopy 
A microscope that uses a beam of accelerated electrons to imagine a specimen is called 
an electron microscope (EM). It utilizes the same basic principles as light microscope. 
Instead of glass lenses, condenser lenses are used in the electron microscope because 
of glass does not pass electrons. The topology, morphology, composition and crystallo-
graphic information of the substances can be obtained. 
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3.3.1 Transmission Electron Microscopy 
Transmission Electron Microscopy (TEM) is the original form of electron microscopy and 
a great tool for the characterization of nanoparticle size, size distribution and morphol-
ogy. The principle of the TEM is almost the same as that of the light microscope, but the 
difference is that it uses electrons instead of light. It means that electrons of much lower 
wavelength make it possible to get a resolution a thousand times better than with a light 
microscope. (26) In this study, TEM was used to find a structure of chitosan nanoparti-
cles. 
3.3.2 Scanning Electron Microscopy 
Scanning Electron Microscopy (SEM) is one of the three types of electron microscopes 
and used in many fields, including medical and materials research. The principle of SEM 
is very similar to that of TEM. The significant difference between those electron micros-
copy techniques is that TEM electrons transmit though the specimen, while the SEM 
electron beams scan across the specimen. In this thesis project, SEM was used for get-
ting an idea about the distribution of chitosan nanoparticles on the polymeric film. 
3.4 Ultraviolet-Visible Spectroscopy 
Ultraviolet-Visible Spectroscopy (UV-Vis) is one of the spectroscopic methods, and it has 
been in general use for the last 35 years. During those years, it has become the most 
important analytical instrument in the laboratory. UV-Visible spectrometry has many ben-
efits such as its simplicity, versatility, speed, accuracy and cost-effectiveness. (27) 
 
Figure 7. Light spectrum chart. UV radiation is called radiation that occurs in range of 100-400 
nm and visible light appearing 400-800 nm radiation. 
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Ultraviolet (UV) radiation is electromagnetic radiation. UV radiation is called radiation 
that occurs in the range of 100-400 nm and visible light is radiation appearing at 400-800 
nm (Figure 7). The molecules may absorb visible or UV light at specific wavelengths, 
consequently the electrons of the molecule become excited. Excitation is possible only 
at specific wavelengths, which correspond to the energy that is needed to displacement. 
When a molecule absorbs energy (which is corresponding to the energy that is needed 
to displacement), an absorption band is detected in the absorption spectrum. This 
method utilizes the phenomenon known as UV-spectroscopy or UV-Vis spectroscopy, 
when the visible light region is involved in the measurements. A UV spectrum is obtained 
by recording the absorbed radiation intensity as a function of the wave number. (28) 
In this thesis project, UV-Vis was used for the detection of drug content on nanoparticles 
and thin polymeric films as well as to obtain drug release curve by using NanoDrop 2000c 
Spectrophotometer, which has a wavelength range from 190 to 840 nm. 
In this thesis project, a standard curve was prepared on different concertation of lidocaine 
hydrochloride with the absorption of spectra by using UV-Vis spectrophotometer. Cali-
bration curves were performed for the standards three times at five different concentra-
tions. The method was linear in the lidocaine hydrochloride concentration range from 
31.25 to 500 µg/ml (R2 = 0.99). All analyses for encapsulation and drug release studies 
were according to standard curve.  
3.5 Optimization process of drug encapsulated chitosan nanoparticles formulations 
One of the aims of this thesis was to find the most efficient encapsulation degree of 
chitosan nanoparticles. At the beginning of the project, three different synthesis routes 
for the drug encapsulated chitosan nanoparticles were tested. Dialkylcarbocyanine (DiI) 
is a lipophilic carbocyanine dye that was used as model drug for optimizing the formula 
before using lidocaine hydrochloride. For all three different drug loaded chitosan nano-
particle preparations, the same ratio of chitosan and tripolyphosphate anion (5:1) were 
used. 
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3.5.1 Preparation of CHT-DiI-TPP nanoparticles 
In the first synthesis protocol, 200 µl of CHT (5 mg) was added to up to 2 ml of 10 mM 
acetate buffer, pH 5.0. DiI was added in different weight percent (1, 5, 10, 25, 50 and 
100 w %) to chitosan solution by simultaneous mixing. The chitosan-DiI solution was 
stirred at 900 rpm with a MIX 15 eco magnetic stirrer approximately 10 min. 322 µl of 
TPP solution (3 mg/ml) was added dropwise to each tube, mixing simultaneously. The 
CHT-DiI-TPP solutions were stirred at 900 rpm with a MIX 15 eco magnetic stirrer for 4 
hours. 
3.5.2 Preparation of CHT-TPP-DiI nanoparticles 
In the second preparation route, 200 µl of CHT (5 mg) was added to up to 2 ml of acetate 
buffer (10 mM @ pH 5.0). 322 µl of TPP solution (3 mg/ml) was added dropwise to each 
tube under fast stirring.  The solution was stirred at 900 rpm with a MIX 15 eco magnetic 
stirrer for 20 min before DiI was added in different weight percent (1, 5, 10, 25, 50 and 
100 w %) to CHT-TPP solution under mixing. The CHT-DiI-TPP solutions were stirred at 
900 rpm with a MIX 15 eco magnetic stirrer for 4 hours. 
3.5.3 Emulsion based encapsulation of DiI into chitosan nanoparticles 
In accordance with the findings of H. Liu e. al (19), the last experiment was made by 
encapsulating DiI containing dichloromethane (DCM) with the aid of the emulsifying prop-
erty of chitosan in the DCM water emulsion system. In this process, first DiI was added 
in different weight percent (0.5, 2.5, 5.0, 12.5, 25.0, 50.0, 75.0 and 100.0 w %) to 1 ml of 
DCM while sonicating. Acetate buffer (10 mM @ pH 5.0) was added up to 2 ml and 
sonicate approximately 10 min. 200 µl of chitosan (5 mg) was added to solution while 
sonicating and sonicate again 30 min. While stirring, 332 µl of TPP (3 mg/ml) was added 
to solution and sonicate and vortex. Vials were left in the stirrer (900 rpm) for 2 hours. 
After 2 hours, DCM was evaporated by heating the sample (36°C) while stirring. 
3.6 Collecting the particles 
Particles were collected by using the same protocol for each batch. One drop of 1 M 
sodium hydroxide (NaOH) was added per milliliter of CS-NPs solution, and the solution 
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was centrifuged with a ScanSpeed Mini microcentrifuge (LaboGene, Denmark) at 12 000 
rpm for 10 min. The pellet was washed twice with 2 ml of Milli-Q water and centrifuged 
at 12 000 rpm for 10 min between washes. However, if weight percent of DiI was 50 w% 
or more, the solution was centrifuged for 15 min instead of 10 min. After washes, 2 ml of 
acetate buffer (10 mM @ pH 5.0) was added on the nanoparticle pellet and sonicated for 
30 min. 
3.7 Hydrodynamic size 
Hydrodynamic size values of chitosan nanoparticles were investigated by using Dynamic 
Light Scattering (DSL, Malvern, Zetasizer Nano ZS). For the measurement, 150 µl from 
the chitosan nanoparticle stock (9 mg/ml of particles) was added to 1.35 ml of acetate 
buffer (10mM @ pH 5.0) and sonicated 30 min before measurement. 
3.8 Determination of drug encapsulation degree for differently prepared particles 
For the drug loading degree determination, a predetermined amount of ethanol was 
added to nanoparticle pellet and sonicated 30 min. Tubes were left on Vortex Mixer VX-
200 (Labnet, Edison, USA) shaker for 2 hours. After 2 hours, tubes were centrifuged (12 
000 rpm, 7 min) and supernatant was collected. Ethanol was added to the pellet, tubes 
were sonicated and vortexed regularly for 30 min and left on the shaker overnight. Su-
pernatant was collected again by using the same protocol as earlier. If the pellet was still 
pink, ethanol was added and left in the shaker for 4 hours. Supernatant was collected. 
Each supernatant was measured by using Nanodrop 2000c UV-Vis spectrophotometer 
(Thermo Scientific, USA) λ= 260 nm. 
3.9 Encapsulation of lidocaine into chitosan nanoparticles 
After optimization of the drug encapsulation for the formulation the model drug, DiI, was 
replaced with the actual drug molecule, lidocaine hydrochloride. See sections 3.5-3.8 
(excluding 3.5.3). All preparation process was made in different weight percent of lido-
caine hydrochloride (1, 5, 10, 25 and 50 w %). Lidocaine hydrochloride in different weight 
percent (1, 5, 10, 25 and 50 w %) was used in the all preparation processes. 
16 
 
  
On the basis of the preliminary tests, the lidocaine hydrochloride incorporation work was 
performed using protocol synthesis that was slightly modified from the protocol that is 
explained in section 3.5.3. The protocol was as follows: 5 mg of lidocaine hydrochloride 
was dissolved in 2 ml of DCM and sonicated 30 min. 400 µl of chitosan (25 mg/ml) was 
dissolved in 936 µl of acetate buffer (10 mM @ pH 5) and added to the DCM-lidocaine 
solution while sonicating. After 30 min sonication and 3 min homogenization, 664 µl TPP 
(3mg/ml) was added to the solution while stirring. CHT-DCM-lidocaine-TPP solution was 
stirred at 500 rpm with a MIX 15 eco magnetic stirrer for approximately 1 hour. After-
wards, the content of DCM in the lidocaine hydrochloride encapsulated chitosan-TPP 
particles was evaporated by heating the sample (36°C). The obtained sample was ly-
ophilized. 
 
Figure 8. 50w% of lidocaine hydrochloride was dissolved in DCM (dichloromethane) and chitosan 
(25 mg/ml) was dissolved in acetate buffer solution (10 mM @ pH 5) separately. After-
wards, the chitosan solution was added to the DCM-lidocaine solution. After the ho-
mogenization of the obtained emulsion, TPP (3mg/ml) was added under stirring. 
Figure 8 shows the synthesis of lidocaine hydrochloride encapsulated chitosan nanopar-
ticles. In this method, DCM is used for emulsified chitosan.  
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3.10 Preparation of bi-layered polymeric film based patches 
Earlier studies have shown that the use of polymers hydroxypropyl methyl cellulose 
(HPMC) and hydroxypropyl cellulose (HPC) to manufacture thin polymeric films give de-
sirable properties to the film such as thickness and elastics. (25) 
In this thesis, two different binders, ethanol and isopropanol alcohol, were tested in ac-
cordance to the findings of M. Preis et. al. (25) The solvent starts to slightly dissolve the 
film to obtain stickiness for adhering it to the surface of the other film. In addition, different 
combinations of selected polymers were tested to be as a base and an upper layer. 
Table1 gives the different combinations of polymers and solvent. Microcrystalline cellu-
lose (MCC) was used to manufacture a rough surface on base layer because film at-
tached more easily to the rough surface than to the smooth surface. 
Table 1. Bi-layer polymeric films manufacturing by paste method (+/+ both layers swelling; -/+ 
only upper layer swelling; +/- only base layer swelling). 
Base layer Upper layer Spray Result 
HPMC + MCC HPMC Ethanol +/+ 
HPMC + MCC HPC Ethanol +/+ 
HPMC + MCC HPC Isopropanol -/+ 
HPC + MCC HPMC Ethanol +/+ 
HPC + MCC HPMC Isopropanol +/- 
When the base layer was made by using HPMC-MCC polymer and the upper layer was 
made from the same polymer (HPMC), the spray solution had to be ethanol because of 
HPMC does not swell with isopropanol. However, when the solvent was ethanol, it was 
hard to paste it on the base layer because both the films started to swell with ethanol. In 
addition, dry film curled up. Preferable result was gotten when isopropanol was used as 
a binder. The film was easier handle because HPC was the only polymer that could swell 
in isopropanol. Therefore, HPMC films could easily be applied onto the isopropanol-wet-
ted base layer. 
3.10.1 Hydroxypropyl cellulose (HPC) film preparation as supporting layer of bi-layered 
film 
The thin polymeric film was made from 15 % hydroxypropyl cellulose (HPC), and 5% 
microcrystal cellulose (MCC) was used as a filling material (table 2). Milli-Q water was 
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used as a solvent. Transparent copier film (Folex imaging, X-10.0) was used as a liner, 
and the film was casted by using film casting knife Film Applicator MULTICATOR 411 
(Erichsen, Germany). The thickness of the wet film was 500 micrometers (casting 
height). This HPC-MCC film was used as a base layer. 
3.10.2 Preparation of hydroxypropyl methyl cellulose (HPMC) films as an upper layer of 
bi-layered film 
An upper layer was made from 10 % hydroxypropyl methyl cellulose (HPMC), and 2 % 
glycerol was used as a plasticizer (Table 2). Milli-Q water was used as a solvent. Trans-
parent copier film (Folex imaging, X-10.0) was used as a liner, and the film was casted 
by using film casting knife Film Applicator MULTICATOR 411 (Erichsen, Germany). The 
thickness of the wet film was 200 micrometers (casting height). 
Table 2. Film formulations used for layers of bi-layered films manufactures – amounts in %. 
LAYER UPPER SUPPORTING 
Film former HPMC HPC 
Polymer 10 15 
Glycerol 2 - 
MCC - 5 
Particles 48 - 
Water 40 80 
In order to incorporate lidocaine-encapsulated CH-NPs into HPMC films, the particles 
were simply mixed with the polymer solution before casting. It was decided to use 50 w% 
of lidocaine hydrochloride loading for film preparation because it gave the best loading 
efficiency in the preliminary tests. Predetermined amount of particles (5.86 mg) which 
corresponds to 50 w% of lidocaine hydrochloride on films were mixed with 2.4 g of ace-
tate buffer (10 mM @ pH 5) and sonicated 30 min. First, 1 ml of film solution was mixed 
well with the particle suspension and then added to the rest of the film solution. Particle-
film solution was stirred at 120 rpm with a MIX 15 eco magnetic stirrer for approximately 
1.5 hour before casting. Furthermore, free lidocaine hydrochloride film (not containing 
CH-NPs) was prepared by using the same protocol. Pure lidocaine hydrochloride was 
mixed with HPMC polymer and added to the solvent. 
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3.10.3 Paste method for manufacturing bilayer polymeric film 
M. Preis et al studied different manufacturing of bi-layered films. (25) On the basis of this 
study, it was decided to use the paste method in this project. Films were prepared as 
described in sections 3.11.1 and 3.11.2. 
 
Figure 9. Bi-layered thin polymeric film. Base layer has rough surface because of MCC and trans-
parent drug-loaded HPMC film layer is completely bound to the base film. 
As the second layer’s film sheets were slightly smaller (3.2 cm x 3.2 cm) than the base 
film (3.5 cm x 3.5 cm), potential drug load of the second layer was completely shielded 
from one side. HPMC film pieces were applied onto the isopropanol-wetted HPC-MCC 
film. As shown in Figure 8, the smooth drug-loaded layer was completely bound to the 
rough film surface. 
3.11 Drug release studies from polymeric film 
First films were cut in the squares with the dimensions of 3.2 cm x 3.2 cm (10 cm2). The 
pieces were soaked to the dissolution medium that consisted of 2 ml of 10 mM acetate 
buffer, pH 5.0. The release was performed at room temperature, with a rotation speed of 
120 rpm with a MIX 15 eco magnetic stirrer. After 35 min, the solution was analyzed by 
using Nanodrop 2000c UV-Vis spectrophotometer (Thermo Scientific, USA), λ= 260 nm. 
All the determinations were made in triplicate. Films that included lidocaine hydrochloride 
loaded nanoparticles were compared with free lidocaine hydrochloride films. 
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3.12 Franz Cell Diffusion 
The release of lidocaine hydrochloride from lidocaine-encapsulated CH-NPs was deter-
mined by using Franz cell diffusion with a diffusion area of 6.25 cm2. Prepared films were 
cut in the squares with the dimensions of 2.5 cm x 2.5 cm. Cellulose Acetate membrane 
filters which have a dimension of 0.45 µm and a pore size of 1.2 µm (Whatman, GE 
Healthcare Life Sciences) was used as membrane. First, the membrane was wetted by 
soaking in the receptor media (10 mM acetate buffer, pH 5) for 30 min. After 30 min, the 
membrane was applied to the dosage wafer. The prepared film was placed onto the 
membrane. The plastic ring was placed on top of the dosage wafer. The receptor com-
partment (capacity 4 ml) was filled with 10 mM acetate buffer (pH 5), and the hydrody-
namics in the receptor compartment was maintained by stirring with a magnetic stirrer. 
The donor formulation is shown in Figure 10. Carefully the dosage wafer with membrane 
and the film was moved on top of the glass disk and the clamp was applied for removing 
pressure. 
 
Figure 10. Franz Cell Diffusion donor formulation top of the magnetic stirrer. 
Approximately 2 ml of the solution from the receiver medium was removed at regular 
intervals, 30, 60, 120, 180 and 240 min. Drug concentration (µg/ml) was measured by 
using UV-Vis, at 260 nm. All the determinations were made in triplicate for each film. Flux 
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from the film that included lidocaine-encapsulated CH-NPs was compared with flux from 
the free lidocaine hydrochloride polymeric film. 
Flux (J), which means the amount of permeant crossing the membrane in time, was 
calculated by using the formulation: 
𝐽 =
𝑐
𝐴
 
where c is the drug content on receiver medium and A is the area of the patch. The unit 
of flux is µg/cm2. 
4 Results and Discussion 
4.1 The encapsulation capacity of CHT-NP prepared with different routes chitosan na-
noparticles 
4.1.1 The encapsulation capacity of CHT-DiI-TPP nanoparticles and CHT-TPP-DiI na-
noparticles prepared by ionic gelation method 
In this thesis, different synthesis routes were tried for the encapsulation of the lidocaine 
in the CHT-NP in order to find the route with the highest drug encapsulation degree. As 
a starting hydrophobic dye molecule (DiI) was used as model drug. The obtained DII 
loading degrees are presented in Table 3. 
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Table 3. Loading weight percent and yield of CHT-DiI-TPP nanoparticles and CHT-TPP-DiI na-
noparticles. Lines on color orange present CHT-DiI-TPP nanoparticles and white lines 
present CHT-TPP-DiI nanoparticles. 
Starting DiI w/w%   Loaded DiI w/w% Yield % 
1 CHT-DiI-TPP 0.69 69.25 
 CHT-TPP-DiI 0.64 64.02 
5 CHT-DiI-TPP 4.68 93.67 
 CHT-TPP-DiI 4.22 84.49 
10 CHT-DiI-TPP 5.89 58.90 
 CHT-TPP-DiI 9.25 92.55 
25 CHT-DiI-TPP 23.00 92.00 
 CHT-TPP-DiI 22.59 90.34 
50 CHT-DiI-TPP 43.35 86.69 
 CHT-TPP-DiI 41.46 82.93 
100 CHT-DiI-TPP 100.92 100.92 
 CHT-TPP-DiI 85.17 85.17 
Drug loading degree and yield in CHT-NPs did not result in significant differences when 
they were prepared with the routes given in section 3.5.1 and 3.5.2 (table 3). For all 
starting weight percent of DiI, yield of DiI were approximately the same with both synthe-
ses. The DiI preparations even resulted in 100 w/w% loading as the highest loading de-
gree for the preparation route of explained in section 3.5.1. Most of the loading degrees 
also resulted in almost 80-90 % loading efficacy relative to the starting drug amount. 
4.1.2 The encapsulation capacity of emulsion based chitosan nanoparticles for DiI 
In this experiment, DiI was attempted to be dissolved in DCM before adding in 10 mM 
acetate buffer. Afterwards chitosan and TPP was added, and the protocol was followed 
as given in section 3.5.3. Table 4 shows low values for the drug loading amount and 
yield for the loading process. The obtained low values mean that DiI cannot be success-
fully incorporated into CHT-NP particles via the synthesis route of emulsion based CHT-
NP preparation. It could be due to the low solubility of DiI in DCM, which also may lead 
to an unsuccessful emulsification and encapsulation process. 
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Table 4. Emulsion based encapsulation of DiI into chitosan nanoparticles. Both values (loading 
w% and yield) were quite low with this synthesis.  
Starting DiI w/w% Loaded DiI w/w% Yield % 
0.5 0.22 43.65 
2.5 0.92 36.59 
5.0 3.68 73.60 
12.5 3.50 28.01 
25.0 3.62 14.50 
50.0 1.48 2.94 
75.0 1.74 2.31 
100.0 1.88 1.88 
Compared all values of different synthesis, it shows that emulsion based encapsulation 
of DiI into chitosan nanoparticles results with  the lowest loading weight percent and yield 
with the model DiI. The best synthesis protocol was found to be the preparation route 
described in 3.5.1, in which DiI was mixed with chitosan solution after the TPP was added 
for ionic gelation process. 
4.1.3 The encapsulation capacity of CHT-lidocaine-TPP nanoparticles and CHT-TPP-
lidocaine nanoparticles 
After optimization of the drug encapsulation for the formulation DiI molecule, DiI was 
replaced with the actual drug lidocaine hydrochloride. Table 5 shows loading weight per-
cent and yield of CHT-lidocaine-TPP nanoparticles and CHT-TPP-lidocaine nanoparti-
cles.  
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Table 5. Loading weight percent and yield of CHT-lidocaine-TPP nanoparticles and CHT-TPP-
lidocaine nanoparticles. Orange rows present CHT-lidocaine-TPP nanoparticles and 
white rows present CHT-TPP-lidocaine nanoparticles. 
Starting lidocaine w/w%   
Loaded lidocaine 
w/w% 
Yield % 
1 CHT-Lidocaine-TPP n/a n/a 
 CHT-TPP-Lidocaine 2.00 200.00 
5 CHT-Lidocaine-TPP 1.56 31.11 
 CHT-TPP-Lidocaine 8.26 165.14 
10 CHT-Lidocaine-TPP 2.27 22.67 
 CHT-TPP-Lidocaine 16.74 167.41 
25 CHT-Lidocaine-TPP 4.00 16.00 
 CHT-TPP-Lidocaine 41.26 165.05 
50 CHT-Lidocaine-TPP 16.67 33.33 
 CHT-TPP-Lidocaine 82.88 165.77 
The preparation process in which TPP was added to chitosan solution before adding the 
lidocaine hydrochloride (as described in section 3.5.2) resulted in higher drug amount 
compared to the actual starting lidocaine amount. The obtained high values may be a 
result of the structural changes in lidocaine molecule at the detection WL of 260 nm with 
the UV-VIS spectrophotometer for this preparation route of drug incorporation. Whereas, 
preparation process in which lidocaine was added to chitosan solution before TPP addi-
tion resulted in lower yield and loading weight percent of lidocaine compared to the ob-
tained efficiency with the model molecule DiI. 
4.1.4 The encapsulation capacity of emulsion based encapsulation of lidocaine into 
chitosan nanoparticles 
In this preparation process of lidocaine encapsulated chitosan nanoparticles, lidocaine 
was dissolved in DCM, and chitosan was dissolved in acetate buffer solution separately; 
in other words, the protocol described in section 3.5.3 was followed. Table 6 shows load-
ing yield and loading degree of lidocaine on CH-NPs. 
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Table 6. Loading efficiency weight percent and loading degree of lidocaine hydrochloride on CH-
NPs. 
Starting lidocaine 
w/w %  
Yield % Loaded Lidocaine w/w% on Particles 
1 n/a n/a 
5 42,67 2,13 
10 66,67 6,67 
25 19,33 4,83 
50 42,67 21,33 
In this experiment, loading yield was between 40-70 %, but the loading degree on CH-
NPs was changing. However, the highest loading degree was obtained with the starting 
50 w/w % lidocaine loading. Therefore, this loading route was used in the thin polymeric 
films. 
4.2 Characterization of lidocaine-encapsulated CH-NPs 
4.2.1 Dynamic Light Scattering 
Dynamic Light Scattering were used to investigate the hydrodynamic size of the particles. 
Chitosan stock solution was not filtered before adding to DCM-lidocaine solution, which 
might be the reason why DSL measurement failed with lidocaine-encapsulated CH-NPs. 
In all measurements, the Polydispersity Index dimensionless (PDI) was greater than 0.7 
indicate, which means that the sample has a very broad size distribution and is probably 
not suitable for the DLS technique. Good PDI value is between 0.1-0.4. However, this 
does not mean that the nanoparticles do not exist. Lidocaine-encapsulated CH-NPs so-
lution might have free chitosan polymers; because they are not filtered, they are too large 
(~120 kDA), which might be the reason of obtained high PDI values. Although DLS is 
one of the most important tools in the characterization of nanoparticles, it is quite sensi-
tive, and it has limitations in such cases. 
4.2.2 Electron Microscopy 
The observation from transmission electron microscope (TEM) gave information of the 
structure of lidocaine-encapsulated CH-NPs (Figure 11), whereas the analysis with a 
scanning electron microscope (SEM) showed the general appearance of chitosan nano-
particles on the polymeric films. (Figure 12). 
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TEM images show that the encapsulation of lidocaine-encapsulated CH-NPs are in clus-
ters. In addition, they were nearly spherical in shape and the size range of clusters was 
about 150-500 nm.  
 
Figure 11. TEM image of lidocaine-encapsulated CH-NPs with 500 nm scale bar. 
 
Figure 12. SEM image of center of the polymeric film incorporated CH-NPs with 100 µm scale bar 
(A) and SEM image of side of the polymeric film incorporated CH-NPs with 200 µm 
scale bar (B). White dots, some of them are pointed with red arrows, present nanopar-
ticles. 
A B 
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White dots on SEM images present nanoparticles. Images from the center and side of 
the film indicate that the nanoparticles were evenly distributed on the film. However, ac-
cording to the result of Franz Cell Diffusion experiment, white dots might also be air 
bubbles on film. 
4.3 Determination of incorporated lidocaine hydrochloride amount on bi-layered poly-
meric film patches 
For drug release experiment films were cut in 10 cm2 pieces. The hypothesis was that 
10-cm2 piece of the film would have approximately 62.5 µg of lidocaine hydrochloride. 
Table 7 shows that release out of lidocaine hydrochloride was approximately 206 µg of 
lidocaine hydrochloride in 10-cm2 film, whereas release out of the film without CH-NPs 
was approximately 79 µg in the 10-cm2 film. 
Table 7. Incorporated lidocaine hydrochloride amount on bilayer polymeric film patches. Piece 
of the films were soaked in acetate buffer (10 mM @ pH 5.0) and complete release of 
incorporated lidocaine hydrochloride was measured after 35 min. 
 Lidocaine Release  
 1 cm
2 of film (µg) 10 cm2 of film (µg) 
With CH-NPs 20,56 205,56 
Free lidocaine 7,87 78,67 
Figure 13 displays a graph of lidocaine hydrochloride release from drug-loaded nanopar-
ticle films and free lidocaine incorporated films. Three parallel experiments gave the 
same result that the release of lidocaine hydrochloride was three times higher when in-
corporated within CH-NPs than without them. 
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Figure 13. Amount of lidocaine hydrochloride in film compared to the film with chitosan nanoparti-
cles between the films without CH-NPs. Films were soaked in 10 mM acetate buffer 
(pH 5.0) for 35 min before measurement. 
Standard deviation was high in both experiments. This mean that lidocaine hydrochloride 
was not evenly distributed and the lidocaine hydrochloride content depends on which 
part of film is used.  
4.4 Determination of lidocaine release profile from bi-layered polymeric film patches 
by Franz-diffusion cell method 
The lidocaine hydrochloride flux profiles of free lidocaine hydrochloride films and lido-
caine-loaded chitosan nanoparticles films are illustrated in Figure 14. 
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Figure 14. Flux of lidocaine measured by using Franz cell diffusion experiment. The red line is the 
film with lidocaine-loaded chitosan nanoparticles, and the blue line is the film without 
chitosan nanoparticles. 
Results showed that the flux of lidocaine was higher when the formulation contained 
nanoparticles. When the film contained free lidocaine hydrochloride, flux increase first 
faster than with CH-NPS, but after one hour, the flux was approximately constant. There-
fore, the flux was increasing until 180 min when films contained lidocaine-loaded chi-
tosan nanoparticles. This means that drug release from the thin polymeric film is im-
proved because of the nanoparticles.  
However, standard deviation was high when the formulation contained lidocaine-loaded 
chitosan nanoparticles. This means that the lidocaine hydrochloride content depends of 
which part of the film is used. 
5 Conclusion 
This study shows that drug encapsulated chitosan nanoparticle preparation with dye, DiI, 
works and the protocol could be used for future studies with drugs that have similar sol-
ubility properties as DiI. The best synthesis process is when DiI was mixed with chitosan 
solution before TPP was added. 
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As to the lidocaine hydrochloride incorporation into CHT-NPs, the preparation route of 
encapsulating the drug with the emulsification process works more effectively compared 
to the other two encapsulation processes. When the lidocaine incorporation into patches 
is carried out by using the CHT-NPs, nanoparticle-incorporated patches seem to provide 
three times more drug incorporation compared to only lidocaine hydrochloride incorpo-
rated patch formulation. The nanoparticle-incorporated patch formulation seems to pro-
vide a sustained release profile. In addition, flux of lidocaine hydrochloride from films was 
compared using Franz cell diffusion; the results suggest that the flux is higher when the 
formulation contains nanoparticles. 
Film casting with casting knife does not give a homogenous film. One reason might be 
that the casting process is manual and the speed is changing each time. In addition, 
inhomogeneous film might depend of how much film solution is being added on the liner. 
It is, therefore, recommended that next investigation could try to make films by using an 
inkjet printer. Polymer-particle suspension solution could act as an ink, and any size of 
patch could be printed. 
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